Dropprint Genomics
YC W20San Francisco, US · 2 employees · Acquired · 1 known investors
Dropprint Genomics develops software for analyzing individual cell activity in genomic data, serving researchers in immunology and drug discovery. The company reduces the cost and computational complexity of single-cell sequencing and maintains a database of over 1 million immune cells to support target identification using machine learning models.
Founders & leadership· Y Combinator alumni (W20)
Investors · 1
In the news
- AstraZeneca extends AI immuno-oncology R&D pact with Immunaifiercebiotech.com · 2024
- Company - Immunaiimmunai.com · 2022
- BioCentury - Oct. 27 Quick Takes: Advancing ‘atlas’ of immunology, Immunai raises $215Mbiocentury.com · 2021
- Dropprint Genomics - 2025 Company Profile, Funding & Competitors - Tracxntracxn.com · 2021
- Immunai Using Acquisition, Funding to Shift Into Functional Work | GenomeWebgenomeweb.com · 2021
- Immunai Acquires Dropprint Genomics | GenomeWebgenomeweb.com · 2021